ERBB2 and breast carcinoma: Surprisingly, many of the luminal/HER2+ breast cancer cell lines that were sensitive to BRD4 knockdown were subsequently found to be resistant to JQ1 treatment, suggesting that BRD4 also has a bromodomain-independent role in this cell type [96].